Combination drugs for treating obesity

Current Diabetes Reports

Volumn 10, Issue 2, 2010, Pages 108-115

  Greenway, Frank L ^a   Bray, George A ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

Combination drug therapy; Obesity

Indexed keywords

5 HYDROXYTRYPTOPHAN; AMFEBUTAMONE; ANTIOBESITY AGENT; APPETITE STIMULANT; BENZOCAINE; CAFFEINE; CARBIDOPA; DEXNORFENFLURAMINE; EPHEDRA EXTRACT; EPHEDRINE; FENFLURAMINE; HERBACEOUS AGENT; LORCASERIN; MAZINDOL; METFORMIN; METRELEPTIN; NALTREXONE; NORADRENALIN; PHENOBARBITAL; PHENTERMINE; PHENYLPROPANOLAMINE; PLACEBO; PRAMLINTIDE; RECOMBINANT LEPTIN; SEROTONIN AGONIST; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZONISAMIDE;

AMNESIA; ASTHMA; BODY MASS; BODY WEIGHT; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; DIABETES MELLITUS; DIET; DIET SUPPLEMENTATION; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MARKETING; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERTENSION; INJECTION SITE REACTION; INSOMNIA; LIVER TOXICITY; MONOTHERAPY; MORNING DOSAGE; NAUSEA; NONHUMAN; OBESITY; PARESTHESIA; REVIEW; RISK FACTOR; SIDE EFFECT; TASTE DISORDER; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URINARY FREQUENCY; URTICARIA; VALVULAR HEART DISEASE; WEIGHT REDUCTION; WORD FINDING DIFFICULTY; XEROSTOMIA; DRUG APPROVAL; DRUG COMBINATION; DRUG EFFECTS; PHYTOTHERAPY;

ANTI-OBESITY AGENTS; DRUG APPROVAL; DRUG THERAPY, COMBINATION; HUMANS; OBESITY; PHYTOTHERAPY; WEIGHT LOSS;

EID: 77953652112     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-010-0096-4     Document Type: Review

References (50)

1. Bray GA: Obesity is a chronic, relapsing neurochemical disease. Int J Obes Relat Metab Disord 2004, 28:34-38.
2. Bray GA: The Battle of the Bulge. Pittsburgh: Dorrance Publishing Co.; 2007.
3. Health implications of obesity. National Institutes of Health Consensus Development Conference Statement [no authors listed]. Ann Intern Med 1985,103:147-151.
4. Maffei M, Fei H, Lee GH, et al.: Increased expression in adipocytes of ob RNA in mice with lesions of the hypothalamus and with mutations at the db locus. Proc Natl Acad Sci U S A 1995, 92:6957-6960.
5. The Obesity Society: What is Obesity? Available at http://www.obesity. org/information/what-is-obesity.asp. Accessed December 2009.
6. Haddock CK, Poston WS, Dill PL, et al.: Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord 2002, 26:262-273.
7. Stafford RS, Radley DC: National trends in antiobesity medication use. Arch Intern Med 2003, 163:1046-1050.
8. Malchow-Moller A, Larsen S, Hey H, et al.: Ephedrine as an anorectic: the story of the 'Elsinore pill'. Int J Obes 1981, 5:183-187.
9. Dulloo AG: Ephedrine, xanthines and prostaglandin-inhibitors: actions and interactions in the stimulation of thermogenesis. Int J Obes Relat Metab Disord 1993, 17(Suppl 1):S35-S40.
10. Pasquali R, Cesari MP, Melchionda N, et al.: Does ephedrine promote weight loss in low-energy-adapted obese women? Int J Obes 1987, 11:163-168.
11. Astrup A, Toubro S, Cannon S, et al.: Thermogenic synergism between ephedrine and caffeine in healthy volunteers: a double-blind, placebo-controlled study. Metabolism 1991, 40:323-329.
12. Astrup A, Breum L, Toubro S, et al.: The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double-blind trial. Int J Obes Relat Metab Disord 1992, 16:269-277.
13. Greenway FL: The safety and efficacy of pharmaceutical and herbal caffeine and ephedrine use as a weight loss agent. Obes Rev 2001, 2:199-211.
14. Hallas J, Bjerrum L, Stovring H, Andersen M: Use of a prescribed ephedrine/caffeine combination and the risk of serious cardiovascular events: a registry-based case-crossover study. Am J Epidemiol 2008, 168:966-973.
15. Greenway FL, Bray GA: Treatment of hypothalamic obesity with caffeine and ephedrine. Endocr Pract 2008, 14:697-703.
16. Weintraub M, Hasday JD, Mushlin AI, Lockwood DH: A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination. Arch Intern Med 1984, 144:1143-1148.
17. Weintraub M, Sundaresan PR, Madan M, et al.: Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin Pharmacol Ther 1992, 51:586-594.
18. Atkinson RL, Blank RC, Schumacher D, et al.: Long-term drug treatment of obesity in a private practice setting. Obes Res 1997, 5:578-586.
19. Greenway FL, Ryan DH, Bray GA, et al.: Pharmaceutical cost savings of treating obesity with weight loss medications. Obes Res 1999, 7:523-531.
20. Connolly HM, Crary JL, McGoon MD, et al.: Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997, 337:581-588.
21. Ryan DH, Bray GA, Helmcke F, et al.: Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine. Obes Res 1999, 7:313-322.
22. Smith SR, Prosser WA, Donahue DJ, et al.: Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women. Obesity (Silver Spring) 2009,17:494-503.
23. Greenway FL: Clinical studies with phenylpropanolamine: a meta-analysis. Am J Clin Nutr 1992, 55:203S-205S.
24. Kernan WN, Viscoli CM, Brass LM, et al.: Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000, 343:1826-1832.
25. Collipp PJ: The treatment of exogenous obesity by medicated benzocaine candy: a double-blind placebo study. Obes Bariatr Med 1981, 10:123-125.
26. Greenway F, Herber D, Raum W, Morales S: Double-blind, randomized, placebo-controlled clinical trials with non-prescription medications for the treatment of obesity. Obes Res 1999, 7:370-378.
27. Sari R, Balci MK, Cakir M, et al.: Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. Endocr Res 2004, 30:159-167.
28. Knowler WC, Barrett-Connor E, Fowler SE, et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
29. Sari R, Balci MK, Coban E, Yazicioglu G: Comparison of the effect of orlistat vs orlistat plus metformin on weight loss and insulin resistance in obese women. Int J Obes Relat Metab Disord 2004, 28:1059-1063.
30. Aronne LJ, Halseth A, Burns C, et al.: Enhanced weight loss following co-administration of pramlintide with sibutramine or phentermine in obese subjects. Obesity (Silver Spring) 2010, in press.
31. Bray GA, Hollander P, Klein S, et al.: A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003, 11:722-733.
32. VIVUS, Inc. Press Releases. Available at http://ir.vivus.com/releases. cfm. Accessed December 2009.
33. Mitchell JE, Morley JE, Levine AS, et al.: High-dose naltrexone therapy and dietary counseling for obesity. Biol Psychiatry 1987, 22:35-42.
34. Jain AK, Kaplan RA, Gadde KM, et al.: Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res 2002, 10:1049-1056.
35. Anderson JW, Greenway FL, Fujioka K, et al.: Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res 2002, 10:633-641.
36. Greenway FL, Whitehouse MJ, Guttadauria M, et al.: Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring) 2009, 17:30-39.
37. Greenway FL, Dunayevich E, Tollefson G, et al.: Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab 2009, 94:4898-4906.
38. Orexigen Therapeutics 2010 Press Releases. Available at http://ir. orexigen.com/phoenix.zhtml?c=207034&p=irol-news&nyo=0. Accessed December 2009.
39. Gadde KM, Franciscy DM, Wagner HR 2nd, Krishnan KR: Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 2003, 289:1820-1825.
40. Li Z, Maglione M, Tu W, et al.: Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005, 142:532-546.
41. Gadde KM, Yonish GM, Foust MS, Wagner HR: Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. J Clin Psychiatry 2007, 68:1226-1229.
42. Heymsfield SB, Greenberg AS, Fujioka K, et al.: Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999, 282:1568-1575.
43. Smith SR, Aronne LJ, Burns CM, et al.: Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care 2008, 31:1816-1823.
44. Roth JD, Roland BL, Cole RL, et al.: Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci USA 2008, 105:7257-7262.
45. Ravussin E, Smith SR, Mitchell JA, et al.: Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring) 2009, 17:1736-1743.
46. Hendricks EJ, Rothman RB, Greenway FL: How physician obesity specialists use drugs to treat obesity. Obesity (Silver Spring) 2009, 17:1730-1735.
47. Rothman RB: Treatment of obesity with "combination" pharmacotherapy. Am J Ther 2009 May 19 [Epub ahead of print].
48. Oben J, Kuate D, Agbor G, et al.: The use of a Cissus quadrangularis formulation in the management of weight loss and metabolic syndrome. Lipids Health Dis 2006, 5:24.
49. Oben JE, Enyegue DM, Fomekong GI, et al.: The effect of Cissus quadrangularis (CQR-300) and a Cissus formulation (CORE) on obesity and obesity-induced oxidative stress. Lipids Health Dis 2007, 6:4.
50. Oben JE, Ngondi JL, Momo CN, et al.: The use of a Cissus quadrangularis/Irvingia gabonensis combination in the management of weight loss: a double-blind placebo-controlled study. Lipids Health Dis 2008, 7:12.